Price
No data yet.
Social Signal Score
Revenue
$0.00-100.00%Company Profile
- CEO
- Nga Yin Wong
- Sector
- Industrials
- Industry
- General Transportation
- Employees
- 35
- Beta
- 0.31
- Country
- HK
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- -1662.10
Financials
Revenue
$0.00-100.0%Net Income
$-171.9KEBITDA
$-171.9KFree Cash Flow
—EPS (diluted)
$-0.01Shares Outstanding (diluted)
21.07M-91.7%Operating Expenses
$171.9KCash & Debt
$22.7KReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $19.3K | $-150.1K | $-0.24 |
| 2024 | $6.4K | $4.69M | $0.00 |
| 2023 | $618.2K | $-77.34M | $-0.06 |
| 2022 | $14.06M | $-101.67M | $-0.27 |
| 2021 | $10.06M | $-25.15M | $-0.07 |
| 2020 | $4.36M | $-246.7K | $0.00 |
| 2019 | $671.3K | $-683.5K | $-0.03 |
| 2018 | $733.2K | $5.8K | $0.00 |
| 2017 | $773.5K | $-127.6K | $-0.01 |
| 2016 | $443.8K | $19.2K | $0.00 |
| 2015 | $298.4K | $37.4K | $0.00 |
Valuation
COSGhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
37-26.67%Social Signal Score
Mentions (11)
- Newsaccessnewswire.com·4d ago·Negative
Cosmos Health's Brands Reach More Than 40 Countries Across Europe, the Middle East, North America and Asia, Addressing Global Markets Estimated at Approximately $946 Billion More than 15 proprietary brands and product lines, plus 10 branded generics - across nutraceuticals, infection control, advanced formulations, skin care and mother & baby, and branded generics Proprietary brands sold in more than 40 countries - across Europe, the Middle East, North America and Asia, through pharmacies, hospi
View source ↗ - Newsaccessnewswire.com·7d ago·Negative
Cosmos Health's CosmoFarm Reaches Record Annualized Revenue Above $60 Million, Up 4.3x Under Cosmos Health Ownership, as Robotics and AI Build Capacity to Support Over $100 Million in Annualized Revenue Record Q2 2026 revenue of over $15 million, an annualized run-rate of over $60 million, at wholly owned subsidiary CosmoFarm Revenue up 4.3x under Cosmos Health ownership - from ~$14 million in fiscal 2017, the last full year before acquisition, to an annualized run-rate of over $60 million; ~330
View source ↗ - Newsaccessnewswire.com·8d ago·Negative
Cosmos Health's Contract Manufacturing Division Surpasses $20 Million in Implied Revenue and $18 Million in Implied Gross Profit Across Its Record 32.7 Million-Unit Production Pipeline Contract manufacturing pipeline surpasses $20 million in implied revenue at wholly owned subsidiary Cana Laboratories, representing over $18 million in implied gross profit across the life of agreements Gross margins of over 90% - among the highest-margin revenue streams in the Company, with raw materials largely
View source ↗ - Newsaccessnewswire.com·21d ago·Positive
Cosmos Health Moves to Tokenize CCX0722 Intellectual Property in Innovative Non-Dilutive Structure, Eyes $562 Billion Weight-Management Market Prime Ledger engaged to structure an asset-specific, non-dilutive tokenized financing for CCX0722 - backed by intellectual property, with no issuance of Cosmos Health common stock Positions Cosmos Health among the earliest NASDAQ-listed healthcare companies pursuing tokenized IP-backed assets. CCX0722 is an ingestible, hydrogel-based medical device in dev
View source ↗ - Newsaccessnewswire.com·24d ago·Neutral
Cosmos Health Secures Additional 2.5 Million Units Under New Five-Year Contract Manufacturing Agreement with Viofar; Total Orderbook Surpasses 27.5 Million Units 500,000 contracted units of ROSARTIA annually / 2.5 million over five years through a new long-term agreement at wholly owned subsidiary Cana Laboratories Expands Cosmos Health's manufacturing presence in cardiovascular pharmaceuticals, adding production of statin-based lipid-lowering therapies to Cana's growing contract manufacturing p
View source ↗ - Newsaccessnewswire.com·27d ago·Positive
Cosmos Health Launches C-ScrubVet in the UK, Advancing into the $69 Billion Global Animal Health Market First orders received for the Company's veterinary antimicrobial line, which will be marketed under the brand name C-ScrubVet Formulated for dogs, cats, horses, companion and large animals, and supplied in a 500ml pump-dispenser bottle Sales have commenced in the United Kingdom, with additional European markets to follow from Q4 2026 Multichannel strategy initially focused on e-commerce, with
View source ↗ - Newsprnewswire.com·27d ago·Neutral
Cosmos Launches Partner Network to Help Financial Institutions Accelerate Tokenization and Digital Assets Initiatives Initial group of seventeen partners will help banks accelerate tokenized deposits and digital asset initiatives NEW YORK, Sept. 9, 2026 /PRNewswire/ -- Cosmos today announced the launch of the Cosmos Partner Network, bringing together leading industry service providers to help global financial players accelerate digital asset initiatives through the Cosmos Tokenization Suite and
View source ↗ - Newsglobenewswire.com·33d ago·Neutral
Cosmos Health: A Company Transformed — 2026 Year-to-Date A Comprehensive Corporate Summary — January 1, 2026 through August 31, 2026 Revenue record set three consecutive quarters: FY2025 $65.3M (+20%) → Q1 2026 $17.93M (+31%) → Q2 2026 $18.99M (+28.8%) → H1 2026 $36.91M (+29.7%). Annualized adjusted run-rate exceeds $75M.
View source ↗ - Newsglobenewswire.com·39d ago·Neutral
Cosmos Health Strengthens Balance Sheet and Streamlines Capital Structure; Retires $8M ATW Convertible Note One Year Ahead of Maturity, Eliminating Further Dilution From Conversions $8 million senior secured ATW convertible note satisfied, together with all accrued interest, twelve months ahead of its August 2027 maturity and eliminating any further dilution Simplified capital structure, with no effective shelf registration statement or ATM program, and no structured warrants or variable interes
View source ↗ - Newsglobenewswire.com·42d ago·Neutral
Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories.
View source ↗ - Newsglobenewswire.com·47d ago·Neutral
Cosmos Health Enters Saudi Arabia Through Exclusive Distribution Agreement With Innova Healthcare; Secures Initial Purchase Order of 126,000 Sky Premium Life Units, With More Than 5 Million Units Expected Over Initial 5-Year Term Cosmos Health Enters Saudi Arabia. Signs Exclusive Distribution Agreement With Innova Healthcare; Secures Purchase Order of 126,000 Sky Premium Life Units.
View source ↗
Insider trading
Open-market buys and sells by COSG officers and directors.
- Bought
- —
- Sold
- $46.7m
0 trades
16 trades
- Yip Tze Wai Albertsold
- Cheung Koon Wingsold
- Wan Miky Y.c.sold
- Cheung Koon Wingsold
- Cheung Koon Wingsold
- Wan Miky Y.c.solddirector, 10 percent owner, officer: President, Interim CFO·32,585 @ $5.22·$170k·Sep 21, 2018·filing
- Wan Miky Y.c.solddirector, 10 percent owner, officer: President, Interim CFO·678,758 @ $3.21·$2.2m·Aug 10, 2018·filing
- Wan Miky Y.c.sold
19 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in COSG.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.